RxDoctor Payments Data

Maria Felix

Family · Torrance, CANPI 1689174476

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Gilead at 42.3% of the total. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,287in general payments, 2019–2025

Across 221 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$1K
  • Johnson & Johnson$457
  • Merck$452
  • EMD Serono, Inc.$273
  • Napo Pharmaceuticals Inc$235
  • plus $200 from 1 others

What the payments were for

  • Speaking & faculty fees$1132%
  • Food & beverage$4,96394%
  • Education$2114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead78$2,234
Viiv Healthcare Company63$1,437
Johnson & Johnson(2 entities)30$457
Merck20$452
EMD Serono, Inc.14$273
Napo Pharmaceuticals Inc14$235
Janssen Products, LP2$200

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,287 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala282$1,095,210
TriumeqAbacavir/Dolutegravir/Lamivudi102$376,923
OdefseyEmtricitab/Rilpiviri/Tenof Ala76$270,211
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf24$109,874
DovatoDolutegravir Sodium/Lamivudine34$99,374
JulucaDolutegravir/Rilpivirine21$73,103
DescovyEmtricitabine/Tenofov Alafenam18$39,948
JardianceEmpagliflozin69$35,860
OzempicSemaglutide31$28,046
IsentressRaltegravir Potassium12$23,441
TrulicityDulaglutide25$22,044
PifeltroDoravirine12$20,710
Abacavir-LamivudineAbacavir Sulfate/Lamivudine17$9,798
EntrestoSacubitril/Valsartan11$6,961
Testosterone31$6,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$2,234$1,135,158300 claims
Viiv Healthcare CompanyTriumeq, Dovato, Juluca$1,437$549,400157 claims
Janssen Products, LPSymtuza$200$109,87424 claims
MerckIsentress, Pifeltro$452$44,15124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →